Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy.
body image
cystic fibrosis
eating behavior
olfaction
quality of life
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
01
06
2023
received:
12
03
2023
accepted:
07
06
2023
medline:
4
12
2023
pubmed:
11
6
2023
entrez:
11
6
2023
Statut:
ppublish
Résumé
Triple-combination therapy of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to reduce morbidity and mortality in people with cystic fibrosis (PwCF). Although patient body mass index (BMI) favorably increases with ETI treatment, factors contributing to this improvement are poorly characterized. Olfaction contributes to appetite stimulation and anticipation of eating, where higher rates of olfactory impairment (OI) in PwCF may contribute to malnutrition and BMI instability in this population. The authors performed a prospective cohort study analyzing 41 CF patient responses to the Cystic Fibrosis Questionnaire-Revised (CFQR) and the 22-Item Sino-Nasal Outcome Test (SNOT-22) and used generalized estimating equations to understand the change in survey variables from being untreated (baseline) to undergoing 3 months of ETI therapy (follow-up). Patients reported significant improvement in their sense of smell at follow-up (p = 0.0036). Their improvements in sense of smell were not confounded by changes in rhinologic or extranasal rhinologic symptoms. Self-reported quality of life (QoL) improved after 3 months of ETI therapy (p = < 0.0001) as did BMI (p = < 0.0001), but improved sense of smell did not independently mediate these changes in QoL and BMI. Our results support the impression that ETI therapy improves CF-associated rhinologic symptoms and reverses OI, while contributing to improvement in rhinologic QoL. Sense of smell is not an independent mediator of improved QoL and BMI in this population, suggesting that other factors may have a stronger role in these realms. However, given the subjective improvement in sense of smell, additional evaluation of OI using psychophysical chemosensory assessment will clarify the connection between olfaction, BMI, and QoL in PwCF.
Sections du résumé
BACKGROUND
BACKGROUND
Triple-combination therapy of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to reduce morbidity and mortality in people with cystic fibrosis (PwCF). Although patient body mass index (BMI) favorably increases with ETI treatment, factors contributing to this improvement are poorly characterized. Olfaction contributes to appetite stimulation and anticipation of eating, where higher rates of olfactory impairment (OI) in PwCF may contribute to malnutrition and BMI instability in this population.
METHODS
METHODS
The authors performed a prospective cohort study analyzing 41 CF patient responses to the Cystic Fibrosis Questionnaire-Revised (CFQR) and the 22-Item Sino-Nasal Outcome Test (SNOT-22) and used generalized estimating equations to understand the change in survey variables from being untreated (baseline) to undergoing 3 months of ETI therapy (follow-up).
RESULTS
RESULTS
Patients reported significant improvement in their sense of smell at follow-up (p = 0.0036). Their improvements in sense of smell were not confounded by changes in rhinologic or extranasal rhinologic symptoms. Self-reported quality of life (QoL) improved after 3 months of ETI therapy (p = < 0.0001) as did BMI (p = < 0.0001), but improved sense of smell did not independently mediate these changes in QoL and BMI.
CONCLUSION
CONCLUSIONS
Our results support the impression that ETI therapy improves CF-associated rhinologic symptoms and reverses OI, while contributing to improvement in rhinologic QoL. Sense of smell is not an independent mediator of improved QoL and BMI in this population, suggesting that other factors may have a stronger role in these realms. However, given the subjective improvement in sense of smell, additional evaluation of OI using psychophysical chemosensory assessment will clarify the connection between olfaction, BMI, and QoL in PwCF.
Substances chimiques
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Aminophenols
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2165-2171Informations de copyright
© 2023 ARS-AAOA, LLC.
Références
Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med. 2007;28(2):279-288. doi:10.1016/j.ccm.2007.02.011
Ridley K. Elexacaftor-Tezacaftor-Ivacaftor CM: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy. J Pediatr Pharmacol Ther JPPT Off J PPAG. 2020;25(3):192-197. doi:10.5863/1551-6776-25.3.192
Naehrig S, Chao CM, Naehrlich L. Cystic fibrosis. Dtsch Ärztebl Int. 2017;114(33-34):564-574. doi:10.3238/arztebl.2017.0564
Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2020;19(1):68-79. doi:10.1016/j.jcf.2019.05.015
Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet Lond Engl. 2019;394(10212):1940-1948. doi:10.1016/S0140-6736(19)32597-8
Lindig J, Steger C, Beiersdorf N, et al. Smell in cystic fibrosis. Eur Arch Oto-Rhino-Laryngol Off J. 2013;270(3):915-921. doi:10.1007/s00405-012-2124-2
Freitas MR, Vasconcelos DN, Freitas AE, Maia Filho JH, Castro e Silva Cd. Nasal endoscopic and CT scan alterations of the paranasal sinuses as predictors of severity in patients with cystic fibrosis. Braz J Otorhinolaryngol. 2013;79(4):480-486. doi:10.5935/1808-8694.20130086
Kang SH, Meotti CD, Bombardelli K, Piltcher OB, de Tarso Roth Dalcin P. Sinonasal characteristics and quality of life by SNOT-22 in adult patients with cystic fibrosis. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino. 2017;274(4):1873-1882. doi:10.1007/s00405-016-4426-2
Di Lullo AM, Iacotucci P, Comegna M, et al. Cystic fibrosis: the sense of smell. Am J Rhinol Allergy. 2020;34(1):35-42. doi:10.1177/1945892419870450
Beswick DM, Humphries SM, Balkissoon CD, et al. Olfactory dysfunction in cystic fibrosis: impact of CFTR modulator therapy. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21(2):e141-e147. doi:10.1016/j.jcf.2021.09.014
Bacon DR, Stapleton A, Goralski JL, et al. Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort. Int Forum Allergy Rhinol. 2022;12(2):223-226. doi:10.1002/alr.22891
Fahmy M, Whitcroft K. Psychophysical testing in chemosensory disorders. Curr Otorhinolaryngol Rep. 2022;10(4):393-404. doi:10.1007/s40136-022-00429-y
Mattos JL, Rudmik L, Schlosser RJ, et al. Symptom importance, patient expectations, and satisfaction in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(6):593-600. doi:10.1002/alr.22309
Boesveldt S, de Graaf K. The differential role of smell and taste for eating behavior. Perception. 2017;46(3-4):307-319. doi:10.1177/0301006616685576
Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinology. 2016;56(1):1-30. doi:10.4193/Rhino16.248
Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol. 2006;20(3):531-546. doi:10.1016/j.bpg.2005.11.006
Abbott J, Morton AM, Musson H, et al. Nutritional status, perceived body image and eating behaviours in adults with cystic fibrosis. Clin Nutr Edinb Scotl. 2007;26(1):91-99. doi:10.1016/j.clnu.2006.08.002
Fajac I, Daines C, Durieu I, et al. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2023;22(1):119-123. doi:10.1016/j.jcf.2022.08.018
MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Meth. 2002;7(1):83-104. doi:10.1037/1082-989x.7.1.83
Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809-1819. doi:10.1056/NEJMoa1908639